Skip to main content

Table 3 Evidence for effectiveness of anti-hypertensive medicines in NRDL of UEBMI——From RCT

From: Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List

  Dosage form RCT (First author, year) JADAD score Research conclusions Sound support for effectiveness
(Y / N)
 Class B
  Amlodipine benapril oral release dosage form Cao J, 2012 [36] 2 Amlodipine benapril can achieve better antihypertensive effect and reduce adverse reactions, which is worthy of clinical promotion. N
  Enalpril hydrochlorothiazide oral release dosage form Wang X, 2006 [48] 4 The efficacy of combination of enalapril hydrochlorothiazide is better than single use of enalapril in the treatment of mild and moderate primary hypertension. Combination of enalapril hydrochlorothiazide has the same safety and toleration as enalapril. Y
  Imidapril oral release dosage form Jiang X, 2005 [46] 4 Imidapril and Benapril are both similarly effective in the reduction of the peripheral blood pressure and the central blood pressure. Y
  Ramipril oral release dosage form Tao B, 2006 [44] 4 The combination of irbesartan with felodipine or ramipril showed synergist antihypertensive effects. Moreover, the combination of irbesartan with felodipine was superior to combination of irbesartan with ramipril. Y
Rokoss M J, 2005 [45] 5 Beneficial effects of ramipril are observed in the treatment of hypertension and congestive heart failure, prevention of cardiovascular events in high-risk patients, prevention of congestive heart failure, diabetes and other vascular events Y
  Cilazapril oral release dosage form Schiffrin EL, 2008 [49] 4 These results may indicate that treatment with cilazapril and perhaps with other angiotensin-I- converting enzyme inhibitors as well may improve the clinical outcome in hypertension by inducing a regression of abnormal resistance vessel structure and function. Y
 Class A
  Metoprolol injection Lu N, 2006 [37] 2 Metoprolol is effective and safe for patients with unstable angina pectoris. It may significantly lower the risk of refractory angina pectoris. N
 Class B
  Propranolol injection Jiang X, 2001 [39] 2 Combination of propranolol with prazosin caused a signincantly greater reduction in the portal pressure on the third month and the reduction in H/L and responding rate were greater in the treatment group than in the control group in patients with a previous bleeding episode. N
Zuo W, 2007 [38] 3 Propranolol, ISMN and spironolactone in combination can effectively prevent the occurrence of hemorrhage in cirrhotic patients with esophageal varices Y
Calcium antagonist
 Class B
  Diltiazem injection Collaborative Group of Diltiazem, 2005 [47] 4 Intravenous diltiazem therapy is effective and safe for patients with unstable angina pectoris. It may significantly lower the risk of refractory angina pectoris compared with intravenous nitroglycerin. Y
 Class A
  Furosemide injection Huang G, 2008 [40] 3 The use of 125 ml 20% mannitol each time plus 20 mg furosemide is more reasonable than other combinations. Meanwhile, semis mannitol combined with moderate or large dose of albumin has certain advantages too. Y
 Class B
  Torasemide injection Zheng W, 2008 [41] 3 Torasemide injection is an effective and safe drug for the treatment of congestive heart failure with edema. Y
Angiotensin II receptor antagonist
 Class B
  Olmesartan Medoxomil oral release dosage form Liao Y, 2014 [43] 3 Compared with enalapril, Olmesartan Medoxomil has more significant inhibition and reversal effects of left ventricular remodeling in treatment of the morning surge of hypertension. Y
 Class B
  Naftopidil oral release dosage form Lu Q, 2000 [42] 3 The efficacy of Naftopidil in controlling the blood pressure is as efficient as that of Terazosin and both drugs are well tolerated by the patients. Y